Loading…
MasterPharm LLC, a compounding pharmacy in New York, was warned for producing adulterated drug products with serious deficiencies in manufacturing practices that put patients at risk. FDA inspectors found that the company's Finasteride Plus capsules contained an average of 1.49 mg per capsule when labeled as 1.25 mg, and the facility had inadequate processing controls that resulted in cross-contamination and super-potency issues affecting 74 patients who reported adverse events. The company had voluntarily ceased dispensing capsule products and recalled compounded products due to these quality failures.